Clinical outcomes of agalsidase Beta (fabrazyme) in Chinese fabry disease patients with proteinuria: a case series - Top-Institutions - MDSpire

Clinical outcomes of agalsidase Beta (fabrazyme) in Chinese fabry disease patients with proteinuria: a case series

  • By

  • Zelei He

  • Yuanyuan Wu

  • Hong Yang

  • Yijuan Li

  • Ling Xu

  • June 17, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Icahn School of Medicine at Mount Sinai / The Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai / The Mount Sinai Hospital

    New York, NY

    Key Differentiators

    • Nephrology
    • Genetics

  • #2

    University of Alabama at Birmingham (UAB) Hospital
    University of Alabama at Birmingham (UAB) Hospital

    Birmingham, AL

    Key Differentiators

    • Nephrology
    • Genetics

  • #3

    Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai

    Key Differentiators

    • Nephrology

  • #4

    Peking Union Medical College Hospital
    Peking Union Medical College Hospital

    Beijing, Beijing

    Key Differentiators

    • Nephrology

  • #5

    Medical University of Białystok
    Medical University of Białystok

    Białystok, Podlaskie

    Key Differentiators

    • Nephrology

Original Source(s)

Clinical outcomes of agalsidase Beta (fabrazyme) in Chinese fabry disease patients with proteinuria: a case series

  • by Zelei He, Yuanyuan Wu, Hong Yang, Yijuan Li, Ling Xu

  • June 17, 2026

Related Content

Epicardial adipose tissue in cardiovascular diseases: a potential therapeutic target

Multitask Artificial Intelligence–Based Electrocardiogram Tool for Preoperative Cardiac Testing in Noncardiac Surgery: Retrospective Cohort Study of Health Care Utilization and Costs

The association of remnant cholesterol inflammatory index with the risk of major adverse cardiovascular events in patients with angina undergoing percutaneous coronary intervention: a retrospective study